In episode 146, a PREMIUM podcast, Mike and James talk about some timely studies. Mike discusses some interesting results from a study that looked at the simple intervention of taking antihypertensives at bedtime and we find out that this intervention not only has an impact on blood pressure but also produces a further reduction in cardiovascular events. Read more »
In episode 142, Mike and James finish off the elderly, but hopefully not literally, by discussing some key RCTs that help inform us as to a few medications that likely should be part of your discussion/armamentarium with your elderly patients. At the end Mike extols the virtues of low doses and James tells him I told you so.
Show notes Read more »
In episode 119, Mike and James tackle a few final issues of atrial fibrillation - rate vs rhythm control, anticoagulation in the elderly, what do with high INR numbers, and short-term warfarin interruption. Read more »
In episode 118, James and Mike continue their discussion of atrial fibrillation by going into details about the evidence for treating patients with atrial fibrillation and how to make decisions between ASA/warfarin/dabigatran and also what it means to be in or out of the INR therapeutic range. Read more »
In episode 117, Mike and James delve into the first of a few podcasts on options for atrial fibrillation. In this first podcast they look at ways to assess risks and talk at length about a web-based tool that makes the process as easy as possible. The process is so easy that the hearts of both Mike and James start to flutter yet only one of them decides to take warfarin. Read more »
In episode 112, Mike and James discuss the who, what, why, where and when of dabigatran in atrial fibrillation. We look at the data, and then discuss what we as individuals would do when making a decision between dabigatran and warfarin. At the end we both agree to disagree with the fact that we agree to disagree.
Show notes Read more »
In episode 68, we get to the “heart of the matter” of stroke prevention for atrial fibrillation. We find out from Peter Loewen, that it is all a numbers game, and he gives us the tools to deal with this issue. We talk about warfarin and ASA and clopidogrel with respect to their benefits and harms. Read more »